Gastrointestinal Comorbidities Representing a Relative Contraindication to NSAID Use: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study

Stephanie J. Nahas, MD, MDEd

AHSAM 2020 - Poster session
Published on July 17, 2020

2 minute listen

1 minute read

Key messages

  • NSAIDs were the most common acute treatment for migraine in patients with gastrointestinal (GI) comorbidity, perhaps reflecting a lack of alternatives.
  • The high frequency of opioid/barbiturate use in those with GI comorbidities suggests a reliance on treatments not recommended for migraine.
  • New migraine-specific acute treatments without GI contraindications may help address the unmet needs of people with migraine and GI comorbidity.
  • Podcast by Stephanie J. Nahas, MD, MDEd  

Key messages

  • NSAIDs were the most common acute treatment for migraine in patients with gastrointestinal (GI) comorbidity, perhaps reflecting a lack of alternatives.
  • The high frequency of opioid/barbiturate use in those with GI comorbidities suggests a reliance on treatments not recommended for migraine.
  • New migraine-specific acute treatments without GI contraindications may help address the unmet needs of people with migraine and GI comorbidity.

Podcast by Stephanie J. Nahas, MD, MDEd

 

 

Stephanie J. Nahas, MD, MDEd
Associate Professor
Department of Neurology, Thomas Jefferson University, Jefferson Headache Center
Philadelphia, Pennsylvania

 

Stephanie Nahas received her undergraduate degree in biology from Harvard in 1995. She then went to Rush Medical College where, after a brief detour to obtain a Masters degree in instructional technology from the University of Southern California in 1998, she earned her MD in 2001. She completed internship at Rush followed by neurology residency then fellowship in headache medicine at Thomas Jefferson University Hospital. After completing 1.5 years of fellowship training, she joined faculty and became the fellowship Program Director at the Headache Center at Thomas Jefferson University in January 2007, and is currently Associate Professor in the Department of Neurology. She is a dedicated advocate for headache, having attended all but one Headache on the Hill events in Washington, DC since 2007, and is Vice President of the Alliance for Headache Disorders Advocacy since February 2018. Dr. Nahas currently serves as Section Editor for Current Pain and Headache Reports, is Co-Chair of the Primary Front Lines of Headache Care Special Interest Section of the American Headache Society, and also serves on the Nominating Committee and Scottsdale Program Committee for the American Headache Society.

 

Stephanie J. Nahas, MD, MDEd: Allergan (Other Activities) (Consulting Fees (e.g., advisory boards), Other Financial or Material Support, Advisory Board Member/Speaker) Amgen (Other Activities) (Consulting Fees (e.g., advisory boards), Advisory Board Member/Speaker) Biohaven (Other Activities) (Consulting Fees (e.g., advisory boards), Other Financial or Material Support, Advisory Board Member/Speaker) Demos Medical (Other Activities) (Honoraria, Other Financial or Material Support, Author/editor honoraria)electroCore (Other Activities) (Consulting Fees (e.g., advisory boards), Other Financial or Material Support, Advisory Board Member/Speaker) Eli Lilly (Other Activities) (Consulting Fees (e.g., advisory boards), Other Financial or Material Support, Advisory Board Member/Speaker) MedLink Neurology (Other Activities) (Honoraria, Other Financial or Material Support, Author/editor honoraria) Supernus (Other Activities) (Consulting Fees (e.g., advisory boards), Other Financial or Material Support, Advisory Board Member/Speaker)Teva (Other Activities) (Consulting Fees (e.g., advisory boards), Other Financial or Material Support, Advisory Board Member/Speaker) UpToDate (Other Activities) (Honoraria, Other Financial or Material Support, Author/editor honoraria)

 



Headache
Epidemiology


Scan to open on your mobile device